Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple mineral tame a racing heart? new trial tests magnesium for AFib

NCT ID NCT07632157

Symptom relief Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This study tests whether giving magnesium along with the standard drug metoprolol can quickly lower a dangerously fast heart rate in people with atrial fibrillation or atrial flutter. About 196 adults in the emergency room will receive either magnesium or a placebo, plus metoprolol. The goal is to see if the combination works better than metoprolol alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Magnesium sulfate (given intravenously) plus metoprolol
What this could lead to
If it works, this could provide a simple, low-cost way to quickly lower dangerously fast heart rates in people with atrial fibrillation in the emergency room.
What could go wrong
This is a small, early-phase trial (196 participants) testing a common mineral supplement. The benefit may be modest, and there are risks like low blood pressure or slow heart rate. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 196 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 years or older * Able to provide informed consent * Primary diagnosis atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR) greater than or equal to 120 beats per minute * Metoprolol as rate control agent * English speaking Exclusion Criteria: * Hemodynamically unstable patients (SBP \<90, MAP \<65) * Impaired consciousness * Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging * Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis * Rhythms other than atrial fibrillation, such as sick sinus syndrome or wide-complex ventricular response * Acute myocardial infarction * Contraindications to magnesium sulfate (including myasthenia gravis) * Allergy or sensitivity to any study drugs * Previously enrolled in this trial during a different patient encounter * Withdrew from study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation with rapid ventricular response are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation atrial flutter

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial flutter with rapid ventricular response

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Advocate Christ Medical Center Emergency Department (ACMC ED)

    Oak Lawn, Illinois, 60453, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.